Compare DexCom, Inc. (DXCM) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs JD.Com Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while JD.Com Inc trades at $26.9 (market cap $36.62B). The key difference: DexCom, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and JD.Com Inc for 85 Days on average.
| DXCM | JD | |
|---|---|---|
Market Cap | $31.86B | $36.62B |
Volume | 3,607,070 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $34.53 |
52-Week Low | $54.84 | $25.19 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $31.32B | $19.26B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
JD.com is trading at $27.03, up 2.0% today, with strong analyst support showing 32 buy ratings versus just 1 sell. The stock demonstrates solid fundamentals with a low P/E of 17.98 and P/S of 0.2, trading below its $35.86 consensus price target. Recent earnings have consistently beaten expectations, though revenue growth has slowed in 2025 with net income margin declining to 1.13%. The company maintains a robust balance sheet with $234 billion in cash and is pursuing strategic acquisitions including the pending Ceconomy deal.
JD.com presents a compelling value opportunity with significant upside potential to analyst targets, supported by strong cash flow generation and consistent earnings beats. However, investors face risks from slowing revenue growth, regulatory scrutiny of international expansion, and competitive pressures in the Chinese e-commerce sector. The stock's current valuation appears attractive relative to peers, but requires monitoring of execution on strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
